NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK (BPN) MEDICINAL CHEMISTRY SUPPORT PROGRAM (MCSP)

NIH 蓝图神经治疗网络 (BPN) 药物化学支持计划 (MCSP)

• 批准号: 10285340
• 负责人: KEITH BARNES
• 金额: $ 27.01万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-24 至 2021-02-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10285340
• 关键词: Biological; Cognitive deficits; Contracts; Data; Development; Epilepsy; Evaluation; Excretory function; Goals; Grant; Health; Human; In Vitro; Individual; Institutes; Intellectual Property; Investigational Drugs; Investigational New Drug Application; Lead; Legal patent; Logistics; Metabolism; Pharmaceutical Chemistry; Phase; Preparation; Property; Regulation; Research Personnel; Rights; Services; Shipping; Stroke; Toxicology; Treatment Efficacy; United States Dept. of Health and Human Services; United States National Institutes of Health; Universities; absorption; direct application; indexing; lead candidate; lead optimization; nervous system disorder; novel; novel therapeutics; pre-clinical; programs; small molecule; therapeutic development

The National Institute on Neurological Disorders and Stroke (NINDS) and the NIH Blueprint Neurotherapeutics Network (BPN) http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm have a need for the Medicinal Chemistry Support Program (MCSP) to provide a full-service facility and staff who would support a medicinal chemistry program in the late Lead Optimization phase to provide in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET) support to characterize top lead candidates to determine best preclinical candidate and to provide compound logistics of storage and shipping to support the Contributor (Dingledine, Emory University) to develop a novel therapeutic effective in cognitive deficits/epilepsy. This will be achieved by advancing the SPR of their small molecule heterocyclic starting compound utilizing in vitro ADMET to identify novel to differentiate top lead compounds. Candidate molecules have undergone some profiling related to the physicochemical properties and biological activity. The goal is to advance the project to go/no go decision amongst the top compounds provided by the Contributor. The data generated from this contract will be used by NINDS, contributors or sponsored investigators in support of Investigational New Drug (IND) application directed preclinical activities. The results of the efforts of this contract will be the basis to advance preclinical candidate compounds for further development i.e., advanced PK and toxicological evaluation in preparation of IND filings.

国家神经疾病与中风研究所（NINDS）和NIH蓝图 Neurotherapeutics网络（BPN）http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm需要 用于药物化学支持计划（MCSP），提供全方位服务的设施和员工 在晚期铅优化阶段支持药物化学计划，以提供体外吸收， 分布，代谢，排泄和毒理学（ADMET）支持，以表征顶级铅候选者 确定最佳临床前候选人，并提供存储和运输的复合物流以支持 贡献者（埃默里大学丁丁丁）开发一种有效的认知治疗方法 缺陷/癫痫。这将通过推进其小分子异环的SPR来实现 利用体外ADMET来识别新颖的化合物以区分顶级铅化合物。候选人 分子经历了与物理化学特性和生物学有关的一些分析 活动。目的是将项目推进到/不进行决定。 贡献者。本合同产生的数据将由Ninds，贡献者或赞助 支持研究新药（IND）应用的研究人员指示临床前活动。这 该合同努力的结果将是推进临床前候选化合物的基础 进一步发展，即先进的PK和毒理学评估，以准备IND归档。